新型P2X3抑制剂用于治疗神经性疾病
1Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
新型P2X3抑制剂为神经性疾病提供了新的治疗方法. 这些化合物显示出在治疗妇科,尿道,呼吸道和疼痛疾病方面的潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
- 神经科学是一个神经科学.
背景情况:
- 神经性疾病包括一系列影响神经系统的疾病.
- 目前针对这些疾病的治疗方法可能存在局限性或副作用.
- P2X3受体与各种疼痛和炎症途径有关.
研究的目的:
- 引入针对P2X3受体的新型抑制剂.
- 描述含有这些抑制剂的药物成分.
- 探索这些化合物的治疗应用在治疗特定的神经性疾病.
主要方法:
- 新型P2X3抑制剂化合物的合成和表征.
- 制药成分的配方. 制药成分的配方.
- 在体外和/或体内研究,以评估相关疾病模型中的疗效 (细节未提供摘要).
主要成果:
- 识别具有P2X3抑制活性的新化学实体.
- 在神经性疾病的临床前模型中证明这些化合物的潜在效用 (具体结果没有详细说明).
结论:
- 新型P2X3抑制剂代表了一个有前途的治疗策略.
- 这些化合物及其成分适用于治疗妇科,泌尿道,呼吸道和与疼痛相关的疾病.
- 描述的过程有助于制备这些潜在的有价值的治疗剂.
更多相关视频
11:47Real-time Live-cell Flow Cytometry to Investigate Calcium Influx, Pore Formation, and Phagocytosis by P2X7 Receptors in Adult Neural Progenitor Cells
Published on: April 3, 2019
16:36Proteomics to Identify Proteins Interacting with P2X2 Ligand-Gated Cation Channels
Published on: May 18, 2009
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
